Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07022119 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
A Phase 1 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated.
- Active
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT07022119 is a Phase 1 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD) that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 32 participants, below the 786-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07022119, a Phase 1 study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of VX-407 in healthy participants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-407
Study Locations (1)
Kansas
- ICON Lenexa - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2026-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07022119
The ClinicalTrials.gov registry entry for NCT07022119 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (96% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07022119 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT07022119 about?
NCT07022119 is a clinical study titled "A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants". The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of VX-407 in healthy participants.
What is the current status of trial NCT07022119?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-06-12. Estimated completion is 2026-03-03.
What conditions does trial NCT07022119 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD).
What interventions are being tested in trial NCT07022119?
The interventions under investigation include: Placebo (DRUG), VX-407 (DRUG).
Who is sponsoring clinical trial NCT07022119?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07022119 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
RECRUITING · NA
-
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
RECRUITING · Phase 2
-
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
ACTIVE NOT RECRUITING
-
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.